IB Ventures proudly announces its first strategic investment in Saudi Arabia’s biotechnology sector, with a stake in Kure Cells, a pioneering biotech company specializing in CAR-T cell therapies and next-generation cellular immunotherapies targeting cancer and autoimmune diseases.
The Pre-A funding round, totaling $10 million, was led by Wa’ed Ventures, the venture capital arm of Saudi Aramco, with IB Ventures joining as a co-investor.
The announcement took place during the Future Investment Initiative (FII 2025) in Riyadh, marking a major step forward in IB Ventures’ commitment to driving transformation in the Kingdom’s biotechnology ecosystem. The investment underscores the company’s dedication to advancing Saudi Vision 2030 by empowering innovation, local manufacturing, and world-class healthcare capabilities.
This strategic move represents a pivotal milestone for IB Ventures, laying the groundwork for a nationally integrated biotech ecosystem focused on cellular and gene therapies. By partnering with leading local and international players, the company aims to facilitate knowledge transfer, enhance talent development, and create sustainable value within Saudi Arabia’s rapidly growing life sciences sector.
